Nab-paclitaxel plus platinum versus paclitaxel plus platinum as first-line therapy in patients with metastatic or recurrent cervical cancer.
Humans
Female
Uterine Cervical Neoplasms
/ drug therapy
Middle Aged
Paclitaxel
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Albumins
/ administration & dosage
Neoplasm Recurrence, Local
/ drug therapy
Retrospective Studies
Adult
Carboplatin
/ administration & dosage
Aged
Cisplatin
/ administration & dosage
Chemotherapy
Metastatic or recurrent cervical cancer
Nab-paclitaxel
Paclitaxel
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
25 Jun 2024
25 Jun 2024
Historique:
received:
05
05
2024
accepted:
31
05
2024
medline:
25
6
2024
pubmed:
25
6
2024
entrez:
24
6
2024
Statut:
epublish
Résumé
This study aimed to assess the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus platinum versus paclitaxel plus platinum as first-line therapy in patients with metastatic or recurrent cervical cancer. Between October 2020 and March 2022, consecutive patients with diagnosed with metastatic or recurrent cervical cancer were retrospectively recruited in our hospital. Fifty-four patients were treated with nab-paclitaxel plus cisplatin or carboplatin. Twenty-four patients were treated with paclitaxel plus cisplatin or carboplatin. A propensity score matching (PSM) analysis was done using a multivariable logistic regression model. The two groups were compared for objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) in the raw and matched dataset. The nab-paclitaxel group showed a higher ORR than the paclitaxel group both in the raw dataset (72.2% vs. 45.8%; P = 0.025) and matched dataset (81.1% vs. 47.6%; P = 0.008). The median PFS was significantly longer in the nab-paclitaxel group than in the paclitaxel group both in the raw and matched dataset (12 vs. 7 months; P < 0.05). The median OS was not reached in the nab-paclitaxel group compared with 15 months in the paclitaxel group, with a trend toward prolongation. The most common toxicity was hematological adverse events, including grade 3-4 neutropenia, grade 3 anemia and thrombocytopenia in both groups and no statistical differences were observed between the groups (all P > 0.05). Compared with paclitaxel plus platinum, nab-paclitaxel plus platinum may be an effective and tolerable option as first-line therapy for patients with metastatic or recurrent cervical cancer.
Identifiants
pubmed: 38914827
doi: 10.1007/s00432-024-05825-z
pii: 10.1007/s00432-024-05825-z
doi:
Substances chimiques
Paclitaxel
P88XT4IS4D
130-nm albumin-bound paclitaxel
0
Albumins
0
Carboplatin
BG3F62OND5
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
321Subventions
Organisme : Hubei Provincial Natural Science Fund Program (Key Project of Joint Fund)
ID : 2024AFD432
Organisme : Hubei Provincial Natural Science Fund Program (Key Project of Joint Fund)
ID : 2024AFD432
Organisme : Wu Jieping Medical Foundation
ID : 320.6750.2021-02-26
Organisme : Bethune Charitable Foundation
ID : 2023-YJ-041-J-009
Informations de copyright
© 2024. The Author(s).
Références
Alberts DS, Blessing JA, Landrum LM, Warshal DP, Martin LP, Rose SL, Bonebrake AJ, Ramondetta LM (2012) Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: a gynecologic oncology group study. Gynecol Oncol 127(3):451–455. https://doi.org/10.1016/j.ygyno.2012.09.008
doi: 10.1016/j.ygyno.2012.09.008
pubmed: 22986144
pmcid: 4459779
Blair HA, Deeks ED (2015) Albumin-bound paclitaxel: a review in Non-small Cell Lung Cancer. Drugs 75(17):2017–2024. https://doi.org/10.1007/s40265-015-0484-9
doi: 10.1007/s40265-015-0484-9
pubmed: 26541764
Chen J, Shi D, Liu X, Fang S, Zhang J, Zhao Y (2012) Targeting SPARC by lentivirus-mediated RNA interference inhibits cervical cancer cell growth and metastasis. BMC Cancer 12:464. https://doi.org/10.1186/1471-2407-12-464
doi: 10.1186/1471-2407-12-464
pubmed: 23050783
pmcid: 3488331
Chopra S, Kalra B, Mulani J, Jain J, Gurram L, Mittal P, Alone M, Ghosh J, Rath S, Gulia S, Gupta S (2022) Salvage (re)radiation in Oligometastatic and Oligorecurrent Cervical Cancer. Int J Radiat Oncol Biol Phys 114(4):812–819. https://doi.org/10.1016/j.ijrobp.2022.07.002
doi: 10.1016/j.ijrobp.2022.07.002
pubmed: 35850364
Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12(4):1317–1324. https://doi.org/10.1158/1078-0432.Ccr-05-1634
doi: 10.1158/1078-0432.Ccr-05-1634
pubmed: 16489089
Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O’Shaughnessy J (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23(31):7794–7803. https://doi.org/10.1200/jco.2005.04.937
doi: 10.1200/jco.2005.04.937
pubmed: 16172456
Guo X, Sun H, Dong J, Feng Y, Li H, Zhuang R, Wang P, Cai W, Zhou Y (2019) Does nab-paclitaxel have a higher incidence of peripheral neuropathy than solvent-based paclitaxel? Evidence from a systematic review and meta-analysis. Crit Rev Oncol Hematol 139:16–23. https://doi.org/10.1016/j.critrevonc.2019.04.021
doi: 10.1016/j.critrevonc.2019.04.021
pubmed: 31112878
Han S, Liu X, Ju S, Mu W, Abulikemu G, Zhen Q, Yang J, Zhang J, Li Y, Liu H, Chen Q, Cui B, Wu S, Zhang Y (2023) New mechanisms and biomarkers of lymph node metastasis in cervical cancer: reflections from plasma proteomics. Clin Proteom 20(1):35. https://doi.org/10.1186/s12014-023-09427-8
doi: 10.1186/s12014-023-09427-8
Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8(5):1038–1044
pubmed: 12006516
Jiang P, Deng X, Qu A, Jiang W, Guo F, Han Q, Guo H, Wang J (2023) Image Guidance volume-modulated Arc Radiation Therapy concurrently with nab-paclitaxel plus cisplatin for patients with locally Advanced Cervical Cancer: a single-arm dose escalation Trial. Int J Radiat Oncol Biol Phys 115(5):1197–1204. https://doi.org/10.1016/j.ijrobp.2022.11.011
doi: 10.1016/j.ijrobp.2022.11.011
pubmed: 36402358
Kim HJ, Chang JS, Koom WS, Lee KC, Kim GE, Kim YB (2018) Radiotherapy is a safe and effective salvage treatment for recurrent cervical cancer. Gynecol Oncol 151(2):208–214. https://doi.org/10.1016/j.ygyno.2018.08.029
doi: 10.1016/j.ygyno.2018.08.029
pubmed: 30195468
Leath CA 3rd, Straughn JM Jr. (2013) Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials. Gynecol Oncol 129(1):251–257. https://doi.org/10.1016/j.ygyno.2012.12.035
doi: 10.1016/j.ygyno.2012.12.035
pubmed: 23280089
Lee H, Park S, Kang JE, Lee HM, Kim SA, Rhie SJ (2020) Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: a meta-analysis. Sci Rep 10(1):530. https://doi.org/10.1038/s41598-019-57380-0
doi: 10.1038/s41598-019-57380-0
pubmed: 31953463
pmcid: 6969039
Li Y, Zeng J, Huang M, An J, Bai P, Wu L, Zhang R (2017) A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma. Cancer 123(3):420–425. https://doi.org/10.1002/cncr.30328
doi: 10.1002/cncr.30328
pubmed: 27696395
Li K, Chen J, Hu Y, Wang YZ, Shen Y, Chen G, Peng W, Fang Z, Xia B, Chen X, Song K, Wang Y, Zou D, Wang YC, Han Y, Feng X, Yuan J, Guo S, Meng X, Feng C, Chen Y, Yang J, Fan J, Wang J, Ai J, Ma D, Sun C (2024) Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial. Lancet Oncol 25(1):76–85. https://doi.org/10.1016/s1470-2045(23)00531-4
doi: 10.1016/s1470-2045(23)00531-4
pubmed: 38048802
Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J, Cella D (2009) Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 27(28):4649–4655. https://doi.org/10.1200/jco.2009.21.8909
doi: 10.1200/jco.2009.21.8909
pubmed: 19720909
pmcid: 2754911
Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B (1996) Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14(6):1858–1867. https://doi.org/10.1200/jco.1996.14.6.1858
doi: 10.1200/jco.1996.14.6.1858
pubmed: 8656254
Pascual-Pasto G, Castillo-Ecija H, Unceta N, Aschero R, Resa-Pares C, Gómez-Caballero A, Vila-Ubach M, Muñoz-Aznar O, Suñol M, Burgueño V, Gomez-Gonzalez S, Sosnik A, Ibarra M, Schaiquevich P, de Álava E, Tirado OM, Mora J, Carcaboso AM (2022) SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas. J Control Release 342:81–92. https://doi.org/10.1016/j.jconrel.2021.12.035
doi: 10.1016/j.jconrel.2021.12.035
pubmed: 34974029
Shi D, Jiang K, Fu Y, Fang R, Liu XI, Chen J (2016) Overexpression of SPARC correlates with poor prognosis in patients with cervical carcinoma and regulates cancer cell epithelial-mesenchymal transition. Oncol Lett 11(5):3251–3258. https://doi.org/10.3892/ol.2016.4399
doi: 10.3892/ol.2016.4399
pubmed: 27123099
pmcid: 4841103
Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, Arbyn M, Basu P, Bray F, Vaccarella S (2023) Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health 11(2):e197–e206. https://doi.org/10.1016/s2214-109x(22)00501-0
doi: 10.1016/s2214-109x(22)00501-0
pubmed: 36528031
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660
doi: 10.3322/caac.21660
pubmed: 33538338
Tai IT, Tang MJ (2008) SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat 11(6):231–246. https://doi.org/10.1016/j.drup.2008.08.005
doi: 10.1016/j.drup.2008.08.005
pubmed: 18849185
Takekuma M, Hirashima Y, Ito K, Tsubamoto H, Tabata T, Arakawa A, Itani Y, Furukawa N, Murakoshi H, Takeuchi S (2012) Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study. Gynecol Oncol 126(3):341–345. https://doi.org/10.1016/j.ygyno.2012.05.010
doi: 10.1016/j.ygyno.2012.05.010
pubmed: 22609108
Vergote I, Ray-Coquard I, Lorusso D, Oaknin A, Cibula D, Van Gorp T (2023) Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline? Expert Opin Investig Drugs 32(3):201–211. https://doi.org/10.1080/13543784.2023.2179483
doi: 10.1080/13543784.2023.2179483
pubmed: 36803278
Wang B, Sun T, Zhao Y, Wang S, Zhang J, Wang Z, Teng YE, Cai L, Yan M, Wang X, Jiang Z, Pan Y, Luo J, Shao Z, Wu J, Guo X, Hu X (2022) A randomized phase 3 trial of Gemcitabine or Nab-Paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer. Nat Commun 13(1):4025. https://doi.org/10.1038/s41467-022-31704-7
doi: 10.1038/s41467-022-31704-7
pubmed: 35821019
pmcid: 9276725
Wang Y, Zhao J, Liang H, Liu J, Huang S, Zou G, Huang X, Lan C (2023) Efficacy and safety of sintilimab plus albumin-bound-paclitaxel in recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase II trial. EClinicalMedicine 65:102274. https://doi.org/10.1016/j.eclinm.2023.102274
doi: 10.1016/j.eclinm.2023.102274
pubmed: 38106561
pmcid: 10725023
Yu XL, Wu MF, Ding L, Yang J, Bai SM (2021) Enhanced efficacy of Neoadjuvant Chemotherapy with Nab-Paclitaxel and Platinum for locally Advanced Cervical Cancer. Cancer Manag Res 13:9297–9304. https://doi.org/10.2147/cmar.S343602
doi: 10.2147/cmar.S343602
pubmed: 35221720
pmcid: 8866986
Zhang X, Chen J, Liu N, Wang Q, Wu Q, Gao F, Sang Y, Wang P (2022) Camrelizumab (SHR-1210) with carboplatin and albumin-binding paclitaxel in patients with metastatic or recurrent cervical cancer: an open-label, phase 2 trial. J Cancer Res Ther 18(2):482–487. https://doi.org/10.4103/jcrt.jcrt_1851_21
doi: 10.4103/jcrt.jcrt_1851_21
pubmed: 35645118